Individualized tumor response testing for prediction of response to paclitaxel and cisplatin chemotherapy in patients with advanced gastric cancer

Journal of Korean Medical Science

Volumn 25, Issue 5, 2010, Pages 684-690

  Kim, Jee Hyun ^a   Lee, Keun Wook ^a   Kim, Yeul Hong ^b   Lee, Kyung Hee ^c   Oh, Do Youn ^d   Kim, Joonhee ^e   Yang, Sung Hyun ^f   Im, Seock Ah ^g   Choi, Sung Ho ^h   Bang, Yung Jue ^g  

^a Seoul National University Bundang Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Yeungnam University Hospital   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Korea Cancer Center Hospital   (South Korea)

^g Seoul National University Hospital   (South Korea)

^h Isu Abxis Co Ltd   (South Korea)

Author keywords

Antineoplastic agents; Antitumor; Cisplatin; Drug screening assays; Paclitaxel; Sensitivity and specificity; Stomach neoplasms; Therapeutic use

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CISPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG SCREENING; FEMALE; HUMAN; KOREA; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STOMACH TUMOR; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; KOREA; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PACLITAXEL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77955291241     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.5.684     Document Type: Article

References (23)

1. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American society of clinical oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004; 22: 3631-8.
2. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983; 43: 1926-31.
3. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
4. Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK, Ghosh BC, Cotelingam JD, Johnson BE, Minna JD, Ihde DC. Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst 1990; 82: 117-24.
5. Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004; 22: 3618-30.
6. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276-82.
7. Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, Kurbacher CM, Reinhold U, Neuber K, MacKie RM, Chana J, Weaver PC, Khoury GG, Sartori C, Andreotti PE. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs 1999; 10: 437-44.
8. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H, Untch M. Correlation of drug response with the ATP tumorchemosensitivity assay in primary figo stage III ovarian cancer. Gynecol Oncol 2000; 77: 258-63.
9. Kurbacher CM, Cree IA, Brenne U, Bruckner HW, Kurbacher JA, Mallmann P, Andreotti PE, Krebs D. Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. Breast Cancer Res Treat 1996; 41: 161-70.
10. Ugurel S, Schadendorf D, Pfohler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase ii trial of the dermatologic cooperative oncology group. Clin Cancer Res 2006; 12: 5454-63.
11. Kang SM, Park MS, Chang J, Kim SK, Kim H, Shin D, Chung KY, Kim DJ, Sohn JH, Choi SH, Kim J, Yoon EJ, Kim JH. A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer. Cancer Res Treat 2005; 37: 223-7.
12. Moon YW, Choi SH, Kim YT, Sohn JH, Chang J, Kim SK, Park MS, Chung KY, Lee HJ, Kim JH. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer 2007; 109: 1829-35.
13. Han SS, Choi SH, Lee YK, Kim JW, Park NH, Song YS, Lee HP, Kang SB. Predictive value of individualized tumor response testing by atp-based chemotherapy response assay in ovarian cancer. Cancer Invest 2008; 26: 426-30.
14. Kim HA, Yom CK, Moon BI, Choe KJ, Sung SH, Han WS, Choi HY, Kim HK, Park HK, Choi SH, Yoon EJ, Oh SY. The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer. Breast 2008; 17: 19-26.
15. Bepler G, O'Briant K. In vitro chemosensitivity testing of human nonsmall cell lung cancer cell lines. Anticancer Res 1998; 18: 3181-5.
16. Boddy AV, Griffin MJ, Sludden J, Thomas HD, Fishwick K, Wright JG, Plumner ER, Highley M, Calvert AH. Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer. Cancer Chemother Pharmacol 2001; 48: 15-21.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
18. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, James EA, Dewar JA, Preece PE, Andreotti PE, Bruckner HW. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 1996; 7: 630-5.
19. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Muller K, Ackermann T, Gilster TJ, Wilhelm LM, Engel H, Mallmann PK, Andreotti PE. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 1998; 9: 51-7.
20. Sevin BU PZ, Perras JP, Ganjei P, Penalver M, Averette HE. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 1988; 31: 191-204.
21. Bosanquet AG BP. Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined disc assay methodology. Leukemia research 1996; 20: 143-53.
22. O'Meara AT, Sevin BU. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 2001; 83: 334-42.
23. Loong TW. Understanding sensitivity and specificity with the right side of the brain. BMJ 2003; 327: 716-9.